FDA Approves Darzalex Faspro for Treating Multiple Myeloma
WEDNESDAY, Aug. 7, 2024 -- The U.S. Food and Drug Administration has approved Darzalex Faspro (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) for induction and consolidation in patients with newly diagnosed multiple myeloma (MM) who are eligible for an autologous stem cell transplant ...
Cilta-Cel Treatment Safe, Effective for Relapsed/Refractory …
TUESDAY, Oct. 8, 2024 -- Ciltacabtagene autoleucel (cilta-cel) CAR T-cell therapy for relapsed/refractory multiple myeloma (RRMM) results in a deep and durable response, according to a study published online Oct. 4 in Blood.
ASH: Daratumumab Beneficial for Patients With Multiple Myeloma
WEDNESDAY, Dec. 13, 2023 -- For transplantation-eligible patients with newly diagnosed multiple myeloma, the addition of subcutaneous daratumumab combined with bortezomib, lenalidomide, and dexamethasone induction and consolidation therapy and with lenalidomide maintenance therapy (D-VRd) improves progression-free survival.
Can Venclexta be used for Multiple Myeloma? - Drugs.com
Aug 8, 2024 · Although Venclexta is not FDA approved for use in Multiple Myeloma (MM), some research indicates that it may be promising for some MM patients who have failed at least one prior treatment, especially those with the genetic abnormality t(11;14) or with high levels of BCL-2. However, its use is not without controversy.
Multiple Myeloma News & Updates - Drugs.com
Aug 8, 2024 · Darzalex Faspro (daratumumab and hyaluronidase-fihj)-Based Quadruplet Regimen Approved in the U.S. for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant-Eligible HORSHAM, Pa., July 30, 2024 – Johnson & Johnson (NYSE:JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved Darzalex Faspro (daratumumab and ...
FDA Approves Abecma for Relapsed, Refractory Multiple Myeloma
Apr 9, 2024 · The approval is for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Abecma is a one-time infusion, with a new recommended dose range of 300 to 510 x 10 6 CAR-positive T cells ...
Multiple Myeloma - What You Need to Know - Drugs.com
Nov 3, 2024 · Multiple Myeloma. Medically reviewed by Drugs.com. Last updated on Nov 3, 2024. Care notes; Ambulatory; Discharge; Inpatient; Español; Overview; Symptoms; Diagnosis; Treatment; Management; What is multiple myeloma? Multiple myeloma is a cancer of plasma cells. Plasma cells are a type of white blood cell. Plasma cells make antibodies to help ...
List of 59 Multiple Myeloma Medications Compared - Drugs.com
Multiple myeloma is a type of cancer that forms in plasma cells (also called mature B-lymphocytes), which are a type of white blood cell that is made in the bone marrow. Multiple myeloma treatments aim to manage symptoms, slow disease progression, and improve quality of life. They typically involve a combination of therapies, such as:
Tecvayli: Uses, Dosage, Side Effects & Warnings - Drugs.com
Oct 30, 2024 · In multiple myeloma, these plasma cells change, spread rapidly, and replace normal cells in the bone marrow with tumors. On the outside of multiple myeloma cancer cells, there is a large number of proteins called BCMA (short for B-cell maturation antigen). Tecvayli can target the MM cancer cells by binding to BCMA proteins. How does Tecvayli work?
Triplet Therapy Including Belamaf Prolongs Survival in Multiple …
FRIDAY, Feb. 9, 2024 -- For patients with relapsed or refractory multiple myeloma (RRMM), triplet therapy of belantamab mafodotin (belamaf) plus bortezomib and dexamethasone (BVd) improves outcomes, with an acceptable safety profile, according to a study presented during the February 2024 session of the American Society for Clinical Oncology ...